PMS-ARIPIPRAZOLE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
22-10-2022
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ARIPIPRAZOLE
Fáanlegur frá:
PHARMASCIENCE INC
ATC númer:
N05AX12
INN (Alþjóðlegt nafn):
ARIPIPRAZOLE
Skammtar:
15MG
Lyfjaform:
TABLET
Samsetning:
ARIPIPRAZOLE 15MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
30
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ATYPICAL ANTIPSYCHOTICS
Vörulýsing:
Active ingredient group (AIG) number: 0152514003; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2018-07-10
Vara einkenni
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-ARIPIPRAZOLE
Aripiprazole Tablets
Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, Oral
House Standard
Antipsychotic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
DATE OF INITIAL AUTHORIZATION
JUL 10, 2018
DATE OF REVISION:
OCT 17, 2022
Submission Control No: 264122
_pms-ARIPIPRAZOLE Product Monograph _
_Page 2 of 70_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Skin
11/2022
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
.....................................................................................................................
4
1.1
Pediatric
.................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
........................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................... 5
4
DOSAGE AND ADMINISTRATION
........................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.......................................................... 6
4.3
Administration
........................................................................................................
7
4.4
Reconstitution..........................
Lestu allt skjalið
